We raised $103M in our Series C financing, following a series of successful regulatory and commercial milestones. This funding was pivotal in supporting our efforts to expand our portfolio, advance meaningful pharma and biotech partnerships to accelerate biomarker-driven therapies and grow our infrastructure to continue leading global decentralization of comprehensive genomic profiling for cancer.
PGDx pursued and successfully obtained the following Proprietary Laboratory Analyses (PLA) code for the PGDx elio™ tissue complete test:
0250U Oncology (solid organ neoplasm), targeted genomic sequence DNA analysis of 505 genes, interrogation for somatic alterations (SNVs [single nucleotide variant], small insertions and deletions, one amplification, and four translocations), microsatellite instability and tumor-mutation burden
This code became effective and is available for use for dates of service on or after July 1, 2021. The national price established by CMS for PLA 0250U will be available on the 2022 Clinical Lab Fee Schedule once it is published online.
PGDx is featured in Baltimore Business Journal’s 2021 Best in Tech Awards.
The PGDx sample-to-answer kitted liquid biopsy solution analyzes circulating tumor DNA for genomic alterations in cancer. Our 500+ gene assay puts cutting-edge plasma based technology in the hands of scientists researching tumor biomarkers directly from blood samples.
PGDx announced several key collaborations focused on advancing the development of precision diagnostics for both clinical and research applications utilizing the PGDx elio portfolio.
Review a few of the publications to which we’ve contributed to help drive cancer care forward.
One of our scientific founders, Luis Diaz, was appointed by President Joe Biden as a Member of the National Cancer Advisory Board (NCAB). NCAB plays an important role in guiding the Director of the National Cancer Institute (NCI) in setting the course for the national cancer research program.
PGDx was named a 2021 Top Workplace by the Baltimore Sun. Our mission-driven employees are relentlessly working to close the precision oncology gap.
We look forward to an exciting 2022 with you!